Edwards Lifesciences (EW) Cash & Current Investments (2009 - 2026)

Edwards Lifesciences' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $3.7 billion for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 5.82% year-over-year to $3.7 billion in Q1 2026; TTM through Mar 2026 was $3.7 billion, a 5.82% decrease from a year earlier, with the FY2025 full-year figure at $4.2 billion, up 6.3% from the prior year.
• Cash & Current Investments eased to $3.7 billion in Q1 2026 per EW's latest filing, from $4.2 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $4.4 billion in Q3 2024 and bottomed at $512.2 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $1.9 billion (2023), against an average of $2.5 billion.
• Across the five-year window, Cash & Current Investments plunged 57.59% in 2023 and surged 676.24% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $1.2 billion in 2022, then plunged by 57.59% to $512.2 million in 2023, then jumped by 676.24% to $4.0 billion in 2024, then rose by 6.3% to $4.2 billion in 2025, then slipped by 13.13% to $3.7 billion in 2026.
• Per Business Quant, the three latest EW Cash & Current Investments figures stand at $3.7 billion (Q1 2026), $4.2 billion (Q4 2025), and $3.8 billion (Q3 2025).